Eyenovia, Betaliq enter potential reverse merger agreement

News
Article

If executed, the reverse merger would create a new ophthalmic company that pairs two FDA-approved technologies for use in glaucoma patients.

Eyenovia, Betaliq enter potential reverse merger agreement in an effort to combine EyeSOL and Optejet as a treatment for gluacoma - Image credit: Adobe Stock / ©dizain

(Image credit: Adobe Stock / ©dizain)

Eyenovia recently announced its entrance into a non-binding letter of intent debating a potential reverse merger transaction with Betaliq, a clinical stage pharmaceutical company with a therapeutic focus on glaucoma. The potential merger would create a new ophthalmic company that pairs two FDA-approved technologies – Betaliq’s EyeSOl water-free drug delivery technology for use in glaucoma and Eyenovia’s Optejet topical ophthalmic liquid dispensing platform.

Michael Rowe, chief executive officer of Eyenovia, said, ““Following a review of strategic alternatives that we initiated in January, I, along with my fellow Board members, concluded that continuing the negotiation of this potential merger with Betaliq is in the best interests of our company, our team members, patients and shareholders. Under a combined new company, if the transaction is completed, our existing products could continue to be marketed to ophthalmologists and optometrists, while the combination of the EyeSol and Optejet technologies has the potential to create a platform that could fundamentally improve how topical eye medications and products are administered. We look forward to working with the Betaliq team on the completion of due diligence and the negotiation and potential execution of a definitive merger agreement in the coming weeks.”

Barry Butler, chief executive officer of Betaliq, shares similar views to Rowe, adding, “This proposed merger with Eyenovia represents a significant opportunity in the eye care space. The inherent synergies of the EyeSol and Optejet technologies could bring innovative new treatment options to patients with glaucoma as well as other ocular diseases. By leveraging the existing pipelines of Eyenovia and Betaliq with multiple opportunities for pipeline expansion through established partnerships, we believe we can build a leading ophthalmic company.”

Eyenovia is still working on advancing the development of Optejet and remains on time to file for U.S. regulatory approval in the fourth quarter of this year. The company does not intend to discuss or disclose further development regarding the possible merger until a definitive agreement is reached.

Reference
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq. Eyenovia. Published March 20, 2025. Accessed March 24, 2025. https://ir.eyenovia.com/news-releases/news-release-details/eyenovia-enters-non-binding-letter-intent-effect-reverse-merger
Recent Videos
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Shan Lin, MD, and John Berdahl, MD, share their perspectives as ophthalmologists regarding the importance of comanagement.
Robert L. Stamper, MD, overviews his optometric track talk titled Objective Perimetry - Can you see it? at this year's Glaucoma 360 meeting.
Yvonne Ou, MD, outlined lifestyle modifications for glaucoma management that have proven beneficial, including yoga and cycling.
Robert L. Stamper, MD, weighs in on what he think more optometrists should know about glaucoma and current misconceptions concerning glaucoma testing.
John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.
© 2025 MJH Life Sciences

All rights reserved.